arrow
J

Julie S. Deutsch

Johns Hopkins University School of Medicine
H指数:9
被引数:495

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Biomarkers of nivolumab benefit in resectable non-small cell lung cancer

可切除非小细胞肺癌中尼沃鲁单抗获益的生物标志物

Nature
IF48.5
2026-08-120
OA
PP01.93: Associations Between Percent Residual Viable Tumor (%RVT) and Efficacy with Perioperative Nivolumab for Resectable Non-Small Cell Lung Cancer (NSCLC) in CheckMate 77T

PP01.93: 百分比残余存活肿瘤(%RVT)与可切除非小细胞肺癌(NSCLC)中围手术期纳武利尤单抗疗效的关联性研究

2026-05-070
PRE
Society for Immunotherapy of Cancer (SITC) consensus statement on essential biomarkers for immunotherapy clinical protocols

癌症免疫治疗学会(SITC)关于免疫治疗临床方案关键生物标志物的共识声明

2025-03-071
OA
Concordance of Whole-Slide Imaging and Conventional Light Microscopy for Assessment of Pathologic Response Following Neoadjuvant Therapy for Lung Cancer

全切片成像和常规光学显微镜评估肺癌新辅助治疗后病理反应的一致性

2025-01-010
PRE
Immunotherapy response induces divergent tertiary lymphoid structure morphologies in hepatocellular carcinoma
2024-10-251
PRE
Comparing anti-tumor and anti-self immunity in a patient with melanoma receiving immune checkpoint blockade
2024-03-052
OAAI
Immunomodulatory response to neoadjuvant nivolumab in non-metastatic clear cell renal cell carcinoma

非转移性透明细胞肾细胞癌对新辅助nivolumab的免疫调节反应

2024-01-174
OAAI
Association between pathologic response and survival after neoadjuvant therapy in lung cancer
2023-10-3039
OAAI
Whole-Slide Imaging, Mutual Information Registration for Multiplex Immunohistochemistry and Immunofluorescence

全载玻片成像,用于多重免疫组织化学和免疫荧光的相互信息配准

2023-08-013
PRE
Analysis of pathological features and efficacy outcomes with neoadjuvant nivolumab (N) plus platinum-doublet chemotherapy (C) for resectable non-small cell lung cancer (NSCLC) in CheckMate 816
2022-09-014
OA